2,3,5-Triphenyl-2H-tetrazolium chloride Cas:298-96-4 98% Keʻokeʻo/haeʻe melemele crystalline pauda
Helu Helu | XD90154 |
inoa mea kūʻai | 2,3,5-Triphenyl-2H-tetrazolium chloride |
CAS | 298-96-4 |
ʻĀpana Molekala | C19H15N4·Cl |
Kaumaha Molecular | 334.80 |
Nā kikoʻī mālama | 2 a 8 °C |
Kānāwai Kūʻai Kūlike | 29339980 |
Huahana Huahana
Ka nana aku | Keʻokeʻo keʻokeʻo/melemele ʻeleʻele pauda |
ʻO Assay | Min.98% |
Lae hehee | 235 - 245 Deg C |
Nalo ma ka maloo | <3.0% |
Waiwai | 0.5% Max |
Koena ma ka Ignition | Max.0.5% |
Solubility ma EtoH | Holo |
Solubility i loko o ka Ethanol | Akaka a piha |
No kaʻimiʻana i ka hopena maikaʻi o ka hui pūʻana o ka butyrate, Lactobacillus casei, a me L-carnitine i loko o keʻano colitis rat. Ua māheleʻia nāʻiole iʻehiku mau pūʻulu.ʻEhā mau pūʻulu i loaʻa i ka butyrate waha, L-carnitine, Lactobacillus casei a me ka hui pū ʻana o ʻekolu mau mea hana no 10 mau lā.ʻO nā hui i koe he mau mana maikaʻi ʻole a maikaʻi a me kahi hui hoʻopunipuni.Macroscopic, histopathological examinations, and biomarkers like tumor necrosis factor-alpha (TNF-α) and interlukin-1β (IL-1β), myeloperoxidase (MPO), thiobarbituric acid reactive substances (TBARS), and ferric reduced ability of plasma (FRAP). ) ua hoʻoholo ʻia i loko o ke kolonā. Ua hōʻike ka hui ʻana i ka hopena maikaʻi loa i ka hoʻohaʻahaʻa ʻana i ka colitis i hoʻohālikelike ʻia me nā mana.Nā hoʻololi holoʻokoʻa i ka hōʻemi ʻana o TNF-α (114.66 ± 18.26 vs 171.78 ± 9.48 pg/mg protein, P <0.05), IL-1β (24.9 ± 1.07 vs 33.06 ± 2.16 pg/mg protein, P <0.0.05), TBARS ± 0.03 vs 0.49 ± 0.04 μg/mg protein, P <0.01), MPO (15.32 ± 0.4 vs 27.24 ± 3.84 U/mg protein, P <0.05), a me ke kiʻekiʻe o FRAP (23.46 ± 1.2 μL vs 1.2. , P <0.05) e kākoʻo i ka makemake o ka hui pūʻana i ka hoʻohālikelikeʻana i nā mana.ʻOiai ua ʻoi aku ka maikaʻi o nā monotherapies i ka hoʻomaikaʻi ʻana i nā hōʻailona colitis, ʻoi aku ka maikaʻi o ka hui ʻana i ka hoʻomaikaʻi ʻana i nā hōʻailona koʻikoʻi o ka colon oxidative e like me FRAP, TBARS, a me MPO. ke kahua lapaʻau.